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Abstract
Background: Accurate prognosticating is needed when patients are nearing the end of life to ensure appropriate
treatment decisions, and facilitate palliative care provision and transitioning to terminal care. People with a
hematological malignancy characteristically experience a fluctuating illness trajectory leading to difficulties with
prognosticating. The aim of this review was to identify current knowledge regarding ‘bedside’ prognostic factors in
the final 3 months of life for people with a hematological malignancy associated with increased risk of mortality.
Methods: A systematic review of the literature was performed across: PubMed; CINAHL; PsycINFO; and Cochrane
with set inclusion criteria: 1) prognostic cohort studies; 2) published 2004–2014; 3) sample ≥ 18 years; 4) >50%
sample had a hematological malignancy; 5) reported ‘bedside’ prognostic factors; 6) median survival of <3 months;
and 7) English language. Quality appraisal was performed using the Quality In Prognostic Studies (QUIPS) tool.
Results are reported in line with PRISMA guidelines.
Results: The search returned 4860 studies of which 28 met inclusion criteria. Twenty-four studies were rated
moderate quality, three were high quality and one study was deemed to be of low quality. Most studies were set
in the ICU (n = 24/28) and were retrospective (n = 25/28). Forty ‘bedside’ prognostic factors were identified as
associated with increased risk of mortality encompassing the following broad categories: 1) demographics; 2)
physiological complications or conditions; 3) disease characteristics; 4) laboratory blood values; and 5) interventions.
Conclusions: The literature on prognosticating in the final months of life was predominantly focused on people who
had experienced acute physiological deterioration and were being treated aggressively in the in-patient setting. A
significant gap in the literature exists for people who are treated less aggressively or are on a palliative trajectory. Findings
did not report on, or confirm the significance of, many of the key prognostic factors associated with increased risk of
mortality at the end of life in the solid tumour population, demonstrating key differences in the two populations.
Trial registration: This systematic review was not registered.
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Background
Hematological malignancies are a collection of heteroge-
neous neoplasms that are distinct from solid tumours
largely by the presence of symptoms related to bone
marrow failure or suppression [1]. These symptoms
include bleeding, infection and anemia. The underlying
disease and treatment of hematological malignancies can
lead to episodes of acute deterioration that require inten-
sive medical intervention [2]. Approximately 7% of people
with a hematological malignancy admitted to hospital will
become critically ill [3]. However, it is not uncommon for
these patients to recover from close to death deterioration
which can be successfully treated in many instances [4, 5].
People with a hematological malignancy characteristically
experience a fluctuating illness trajectory [5] leading to
difficulties with prognostication [6]. Often times, deterior-
ation is unpredictable and rapid, and can lead to a swift
change in goals of care from curative to palliative [7, 8].
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Palliative care is a holistic approach that aims to improve
quality of life for people with life-threatening illness [9]. Al-
though traditionally viewed as terminal care, palliative care
can be integrated at any time in an illness trajectory, along-
side disease modifying and curative treatment [10]. In con-
trast, terminal care is provided as a patient nears the end of
their life, however there is no agreed upon definition of the
terminal phase in an illness [11]. It is agreed that the ter-
minal phase is a time where goals of care should be focused
on comfort, dignity and symptom management, rather than
control of the cancer [11]. A growing body of literature has
identified that significant challenges exist providing pallia-
tive care in the hematology setting [5]. Specifically, the un-
predictable and fluctuating illness trajectory of people with
a hematological malignancy and potential for rapid deterior-
ation is reported to delay the identification and communica-
tion of transitions from a curative to a palliative focus of
care [12]. These factors act as a barrier to timely palliative
care integration in care and patients’ transition to the end
of life [5]. Hematologists have reported difficulties in prog-
nosticating as a hindrance to palliative care integration [6].
A prognosis is a prediction of possible future outcomes
and is often focused on risk of mortality and time frames of
survival [13, 14]. Predicting time frames of survival is diffi-
cult due to the complex nature of the human body and an
increasing ability for medicine to alter the course of a
disease [14]. This is particularly relevant in the hematology
setting which has seen rapid developments in anti-cancer
therapies (immunologic and targeted agents) in recent years
[15]. Prognosticating near the end of life provides valuable
information for people with a cancer diagnosis, their fam-
ilies and health care professionals [14, 16]. The question
“how long do I have to live?” is one of the most important
and daunting questions a person can ask their health care
team [14]. Although palliative care is recommended to be
integrated early and on a needs basis rather than based on
prognostic information, accurate prognostic information al-
lows health care professionals to know when to initiate open
honest discussion with patients and their families about the
end of life [14]. Ideally, conversations around potential de-
terioration and death should have already taken place earlier
in the disease trajectory during times of clinical stability
[17]. Honest discussions with patients who are nearing the
end of life enable review of the goals of care, in line with the
patient’s wishes, and clarification regarding the patient’s
wishes for their health care management in the future, and
at the end of life [18, 19]. Time for planning has been re-
ported as an important issue for people living with advanced
cancer [20]. Clinicians must be able to prognosticate accur-
ately near the end of life in order to communicate effectively
with patients and their family members, make informed de-
cisions about treatment options, integrate palliative care
when appropriate, and facilitate timing of referral to special-
ist palliative care services and planning for death [6, 14].
We conducted a systematic review of the literature to
identify the prognostic factors in the final 3 months of
life that are associated with increased risk of mortality
for people with a hematological malignancy. The ration-
ale for this review was to provide clinicians with an over-
view of current evidence regarding prognostic factors, to
facilitate provision of palliative care as patients transition
to the end of life. The review was also intended to iden-
tify gaps in the literature and guide future research.
Methods
Data sources
This review is reported in accordance with PRISMA guide-
lines on reporting reviews of the literature [21]. As per an a
priori protocol, a systematic search of the literature was
performed across the following electronic databases: a)
PubMed; b) CINAHL c) PsycINFO; and d) Cochrane Cen-
tral. WHO Clinical Trial Search Portal (www.who.int/trial-
search) was searched to identify relevant studies that are
currently underway or have recently been completed and
ProQuest Dissertation and Theses database was searched
to identify grey literature. Additionally, reference lists of
relevant papers were screened. Key words included: 1)
hematological malignancy; 2) prognostic factors; and 3) end
of life. Related synonyms and Medical Subject Headings
(MESH) were utilised in the search. The protocol was not
registered.
Selection criteria
Decisions for inclusion of studies were made based on
the selection criteria displayed in Table 1. Screening of
search titles, abstracts and full texts was undertaken by a
single person (EB). Challenging decisions regarding the
inclusion of a paper were discussed with a second mem-
ber of the research team (PY, RC or SC).
The search considered prognostic studies that examined
predictive factors of mortality in people with a
hematological malignancy in their final 3 months of life.
Studies were included if the sample had a median survival
Table 1 Selection criteria
Inclusion criteria Exclusion criteria
• English language only
• Human research subjects
with a hematological malignancy
(>50% of study sample)
• Adult patients (≥18 years of age)
• Primary research
• Peer reviewed articles
• Studies from January 2004 to
November 2014
• Prognostic studies (cohort or
case-control)
• Median survival of ≤ 3 months,
(or >50% sample had died in ICU,
or in hospital or within 3 months)
• Reported ‘bedside prognostic factors’
• Editorials and letters
• Discussions / expert
opinion papers
• Non - peer reviewed
• Reports of clinical trials
evaluating the effects of
a specific treatment
(chemotherapy, radiation
therapy, etc.)
• Systematic reviews of
original research
(predictive/prognostic
cohort studies)
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of less than, or equal to, 3 months, or over 50% of the
sample had died at 3 months. It is important to note that
palliative care integration, review of goals of care and end-
of-life care discussions and planning can occur at any
time, not just in the final 3 months of life. During prelim-
inary searching it was identified that studies regarding
prognosticating at the end of life predominantly reported
overall survival of no more than 3 months. This time
period was chosen as it defined a homogeneous popula-
tion and enhanced the ability to generalize results [11].
This time period has been used in other reviews reporting
on prognosticating at the end of life [11, 22]. Additionally,
this time period would be valuable in informing the transi-
tion to the end of life for people with a hematological ma-
lignancy. Studies in any health care setting or health care
facility were included (i.e. at home in the community,
palliative care unit, cancer care ward or intensive care
unit). This wide inclusion criterion was utilised to provide
a broad overview of the current scientific knowledge re-
garding prognosticating for people with a hematological
malignancy at the end of life, and to highlight gaps in the
literature. Research studies published within the last
10 years were included in the review due to the rapidly
evolving nature of health care, specifically in the
hematology setting. Studies were included if >50% of par-
ticipants were people with hematological malignancies, or
if the data reported were analysed independently in case-
control studies comparing prognostic factors between
people with solid tumours and hematological malignan-
cies. All single cohort studies that met inclusion criteria
(not comparison studies) included only participants with a
hematological malignancy. Only studies reporting ‘bedside
prognostic factors’ were included, meaning factors that
are generally available and able to be assessed for in regu-
lar clinical practice by a range of clinicians, which include:
performance and nutritional status; clinician estimates of
survival; symptom burden; routine laboratory tests; quality
of life; and socio-economic factors [11]. More complex
prognostic factors that were excluded included cytogen-
etic tests and molecular markers as these require special-
isation to interpret.
Quality assessment
Quality appraisal was performed using the Quality In Prog-
nostic Studies (QUIPS) tool as it supports a systematic ap-
praisal of bias [23]. The QUIPS is an evidence-based, peer
reviewed, practical system for assessing quality in prognos-
tic studies by assessing bias in essential domains including:
selection bias; confounding; outcome measurement; and
prognostic factor measurement [23–25]. A formal quality
appraisal tool with a scoring system was used to provide
structure to the review however, the limitations of such a
system are acknowledged [26]. Based on a recommendation
from the Cochrane Collaboration, the main focus of quality
assessment in this review was the individual features of the
study rather than the quality appraisal score [26]. Hence,
studies were included regardless of their quality appraisal
score; limitations of the studies were also noted [26]. Each
study was read in full and evaluated independently by a
second member of the research team. Any divergent results
were discussed between two members of the research team
and a single rating was assigned.
Analysis
A formal meta-analysis was not planned or attempted for
this systematic review as the methods, populations, defini-
tions or prognostic factors and results were too heteroge-
neous [27, 28]. The issue of integrating the results of
prognostic studies is not unique to this review and has been
found to be particularly problematic in prognostic studies
due to inconsistent terminology, inadequate reporting and
heterogeneity in study designs [29]. A narrative analysis was
undertaken based on the statistical significance (p value)
and Confidence Interval (CI) for each factor [11].
Results
Study selection
A search of the literature returned 4860 articles. After
duplicates were removed, and titles and abstracts were
screened against the set selection criteria, 37 studies were
read in full, and 28 were found to be relevant and included
in the review. See Fig. Fig. 1 for further details. No grey
literature, or recently completed or ongoing studies, were
identified.
Study characteristics
Of the 28 studies included in the review, 24 investigated
prognostic factors associated with increased risk of
mortality in people admitted to the intensive care unit
(ICU) [30–53]. One study explored prognostic factors in
the context of intracranial hemorrhage in the hospital set-
ting [54] and another included a sample of patients with
invasive aspergillosis, also in hospital [55]. Two studies
measured prognostic factors of palliative patients, one on
referral to a specialist palliative care service (including
in-patients and out-patients) [56], and the other on admis-
sion to a palliative care unit [57]. All but one of the
included studies sampled participants from the in-patient
setting, limiting the generalizability of findings to this
population. Corbett et al. included a population in the
out-patient and in-patient setting referred to a specialist
palliative care service [56]. The studies were purely prog-
nostic single cohort studies, with the exception of two.
Hill et al. [49] and des Ordons et al. [44] employed prog-
nostic case-control cohort designs and compared out-
comes of people with a hematological malignancy
admitted to the ICU against medical controls. The studies
with a single cohort included people with a hematological
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malignancy or in comparison studies, only data on the
group with a hematological malignancy were extracted
and included in the results of this review. Including case-
control studies in this manner did not impact the process
of exploring prognostic factors and is not viewed as a limi-
tation in regards to the aims of this review. Methodo-
logical features of the studies are presented in Table 2.
The majority of sample sizes were small, 21 of the 28
studies had a sample size of <150. Small sample size is a
limitation of prognostic research [29] however, due to the
specific nature of the cohort, it is acknowledged that a
small sample may have been difficult to avoid. The major-
ity of studies were retrospective (n = 25). Country of pub-
lication varied between the studies however they were
primarily conducted in western developed countries that
have similar health care systems. Most of the studies were
conducted at a single centre, with the exception of three
studies [42, 48, 49], which retrospectively reviewed data
from multiple centres via electronic health databases. It is
possible that results of single centre studies can be attrib-
uted only to the site where the research was conducted
due to individual characteristics of that centre not present
in other settings. Many studies had long periods of data
collection; eleven studies collected data for 10 years or
more [31, 37, 42, 45, 48, 50, 51, 53–55, 57]. Collecting data
over long periods can lead to era bias, where changes in
hospital practice and policy, or improved treatments and
technologies can affect patient outcomes. Survival was
measured via ICU mortality, hospital mortality, 30-day
mortality and median survival time. Ideally, prognostic
studies are best compared when there is similar reporting
of survival outcomes [11].
Quality of studies
Utilising the QUIPS tool, 24 studies were rated moderate
quality, three were high quality and one study was deemed
to be of low quality. All studies were included in the
review regardless of their score and their limitations were
noted. The quality appraisal score for each study is
presented in Table 2.
Patient characteristics
Collectively, the study samples had more male participants
(61%) (range 33% [30] to 78% [50]). Participants’ age ranged
Fig. 1 PRISMA Flow diagram for inclusion of studies
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Table 2 Methodological features of studies
Author, Year, Country Design Sample characteristics Hem malig N Analysis Quality rating (QUIPS)
Rabe et al., (2004)
Germany [41]
Retro Admitted to ICU, with pulmonary
infiltrates, requiring ventilation
AML 30 Uni
-
Mod
Soubani et al., (2004)
USA [30]
Retro Admitted to ICU HSCT 85 Uni
Multi
Mod
BaHammam et al. (2005)
Saudi Arabia [51]
Retro Admitted to ICU All 44 Uni
-
Mod
Owczuk et al., (2005)
Poland [37]
Retro Admitted to ICU, requiring ventilation HSCT 40 Uni
Multi
Mod
Naeem et al., (2006)
USA [34]
Retro Admitted to ICU Cord HSCT 44 Uni
-
Mod
Ferra et al., (2006)
Spain [46]
Retro Admitted to ICU All 100 Uni
Multi
Mod
Lim et al., (2007)
UK [33]
Retro Admitted to ICU All 55 Uni
-
Mod
Yang et al., (2007)
Taiwan [31]
Retro Admitted to ICU, requiring ventilation HSCT 41 Uni
-
Mod
Nishida & Palalay, (2008)
USA [36]
Retro Admitted to ICU, requiring ventilation All 37 Uni
-
Mod
Park et al., (2008)
Korea [38]
Retro Admitted to ICU for septic shock Acute leuk 50 Uni
Multi
High
Chen et al., (2009)
Taiwan [54]
Retro Intracranial hemorrhage (in-patient acute setting) AML 51 Uni
Multi
High
Hampshire et al., (2009)
UK [48]
Retro Admitted to ICU (multi-centre) All 7689 -
Multi
Mod
des Ordons et al., (2010)
USA [44]
Retro Admitted to ICU AML 45 Uni
-
High
Burghi et al., (2011)
France [53]
Retro Admitted to ICU, invasive pulmonary
aspergillosis, ventilated
All 67 Uni
Multi
High
Depuydt et al., (2011)
Belgium [43]
Pro Admitted to ICU Allo
HSCT
44 Uni
Multi
Mod
Geerse et al., (2011)
Netherlands [47]
Retro Admitted to ICU All 86 Uni
Multi
Mod
Park et al., (2011)
Korea [39]
Retro Admitted to ICU, with AKI, requiring RRT All 94 Uni
Multi
Mod
Ramos et al., (2011)
USA [55]
Retro Invasive aspergillosis (in-patient acute setting) HSCT 449 Uni
Multi
Mod
Agarwal et al. (2012)
Australia [50]
Retro Admitted to ICU HSCT 146 Uni
Multi
High
Ferra et al., (2012)
Spain [45]
Retro Admitted to ICU Lymphoma 48 Uni
Multi
Low
Hill et al., (2012)
UK [49]
Retro Admitted to ICU (multi-centre) All 147 Uni
Multi
Mod
Yeo et al., (2012)
Korea [32]
Retro Admitted to ICU All 227 Uni
Multi
Mod
Corbett et al., (2013)
Australia [56]
Retro Referred to specialist palliative care service
(in-pt. & out-pt. setting)
All 276 -
Multi
Mod
de Montmollin et al., (2013)
France [42]
Retro Admitted to ICU, with septic shock, pulmonary
origin (multi-centre)
All 218 Uni
Multi
Mod
Namendys-Silva et al., (2013)
Mexico [35]
Pro Admitted to ICU All 102 Uni
Multi
Mod
Price et al., (2013)
USA [40]
Retro Admitted to ICU, requiring ventilation Acute leuk 167 Uni
Multi
Mod
Kripp et al., (2014)
Germany [57]
Pros Admitted to palliative care unit All 290 Uni
Multi
Mod
Boyaci et al., (2014)
Turkey [52]
Retro Admitted to ICU HSCT 48 Uni
Multi
Mod
AML acute myeloid leukemia, ICU intensive care unit, HSCT hematopoietic stem cell transplant (allogeneic and autologous), HM hematological malignancy, Cord
HSCT umbilical cord (source of stem cells) hematopoietic stem cell transplant, alloHSCT allogeneic hematopoietic stem cell transplant, AKI acute kidney injury,
RRT renal replacement therapy, HIV + ve human immunodeficiency virus positive, U univariate statistical analysis / M - multi- multivariable statistical analysis
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from a mean of 32.7 years (SD 8.8) [31] to a median of
70.5 years (range 15–98) [57]. The latter of the ranges
describes a sample from a palliative care unit which may
explain the older population. Only one study reported the
race of the sample, which was: 82% white; 11.7% African
American; and 5% other [30]. No study discussed patients’
socio-economic status or education level. Fourteen studies
included all types of hematological malignancies [32, 33, 35,
36, 39, 42, 46–49, 51, 53, 56, 57]; five sampled patients with
acute leukemia [38, 40, 41, 44, 54]; eight looked at people
who had undergone hematopoietic stem cell transplant-
ation [30, 31, 34, 37, 43, 50, 52, 55]; and one was specifically
focused on people with human immunodeficiency virus
associated lymphoma [45]. The patient population was
predominantly treated with aggressive curative or life-
prolonging intent, as most studies (n = 24) had admission
to the ICU as a criterion for inclusion. [58].
Analysis in studies
Seven of the 28 studies did not conduct multivariable
analysis [31, 33, 34, 36, 41, 44, 51], and therefore did not
account for the effect of multiple explanatory variables on
the variable of interest, limiting the results [59, 60]. This is
likely due to the fact that many study samples were small
and had a limited number of events, i.e., deaths in the con-
text of this review. Due to limitations associated with small
sample sizes and low numbers of events, prognostic factors
identified in univariate and multivariable analysis were in-
cluded in the results of this review. An extensive range of
prognostic factors were measured in the 28 studies. Many
of the studies tested more factors than merited by their
small sample size. As a general rule, at least 10 events are
needed for each prognostic factor to allow for multivariable
regression analysis [61, 62]. In addition, of the 21 studies
that used multivariable analyses, goodness of fit testing was
reported in only seven studies. Williams et al. [63] report
that ‘over fitted’ models with no description of model valid-
ation are a key weakness in prognostic studies.
Prognostic factors identified
A wide range of variables were tested as potential prognos-
tic factors in the studies. Many of these factors were
described inadequately or measured via different methods.
Collectively, 40 bedside prognostic factors were reported to
be significantly associated with increased risk of mortality
in people with a hematological malignancy. These
prognostic factors were conceptualized into the following
categories: demographic; interventions; physiological com-
plications or conditions; disease characteristics; and labora-
tory blood values. Between the studies, certain variables
measured similar concepts, and were therefore aggregated
under a single prognostic factor for ease of analysis. This
occurred for sepsis/infection, coagulopathy, liver dysfunc-
tion, elevated liver enzymes, elevated creatinine or urea,
respiratory distress/failure, decreased level of consciousness
(LOC), cardiovascular function and hemodynamic instabil-
ity. Prognostic factors identified as associated with in-
creased risk of mortality in univariate and/or multivariable
analyses are presented in Additional file 1. Attributes of the
prognostic factors identified as significantly associated with
increased risk of mortality are presented in Table 3.
Demographic
Age was the most commonly studied variable however,
it did not appear to be of prognostic importance. In the
22 studies that investigated this factor, only 30% found
increasing age was significantly associated with increased
risk of mortality in both univariate and multivariable
analyses, in a combined sample of 10,027 people.
Interventions
In terms of interventions, aggressive therapies associated
with critical illness were the most consistent prognostic
factors of increased risk of mortality. Receiving vasopres-
sor support was predictive of, or associated with, increased
risk of mortality in 89% of multivariable analyses models
and 80% of univariate testing in the 15 studies that
measured this variable (total sample n = 1300). Similarly,
receiving mechanical ventilation was predictive of mortal-
ity in 86% of multivariable analyses modelling and 76% of
univariate testing in 18 studies (total sample n = 9702).
Receiving renal replacement therapy in the ICU was also
identified as a significant prognostic factor in 43% of
univariate results (n = 3/7) and in 75% of multivariable
results (n = 3/4) in a total sample of 633 participants.
Ramos and colleagues [55] identified that admission to
an ICU was significantly associated with increased risk
of mortality. This was the only study to identify this
prognostic factor however this may be because this study
was one of few studies that did not examine prognostic
factors of people already admitted to the ICU. Only one
study investigated receiving opiate analgesia and artificial
feeding as prognostic factors, and this study was one of
the two studies conducted in a palliative setting [57].
Physiological complications or condition
Under the category of physiological complications or con-
ditions, prognostic factors related to serious illness and
bone marrow failure or suppression was consistently asso-
ciated with worse survival or was predictive or mortality.
Multi-organ failure was associated with increased risk of
mortality in 75% of univariate analyses and 83% of multi-
variable analyses in the 9 studies that investigated this fac-
tor (total sample n = 657). Hemodynamic instability was
tested in 9 studies, total sample of 8095, and was signifi-
cant in 75% of univariate results (n = 6/8) and 62% of mul-
tivariable results (n = 5/8). Liver failure, renal failure and
cardiac failure were significantly correlated with decreased
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Table 3 Attributes of commonly reported prognostic factors
Prognostic factor Number of
studies
Total # of
pts., N
Univariate analysis
Significant/ tested/
% significant
Multivariable analysis
Significant/ tested/
% significant
Hematological
malignancies tested
Older age 22 10,027 6/20
(30%)
5/16
(31%)
• Acute leukemia
• All hematological malignancies
• AML
• Cord HSCT
• HSCT
Mechanical ventilation 18 9702 13/17
(76%)
12/14
(86%)
• Acute leukemia
• All hematological malignancies
Cord HSCT
• HSCT
• Lymphoma
Vasopressors use 15 1300 12/15
(80%)
8/9
(89%)
• Acute leukemia
• All hematological malignancies
• AML
• Cord HSCT
• HSCT
Renal replacement therapy 7 633 3/7
(43%)
3/4
(75%)
• All hematological malignancies
• AML
• HSCT
Transfusions 4 490 2/4
(50%)
2/4
(50%)
• Acute leukemia
• All hematological malignancies
• HSCT
Admission to intensive
care unit
1 85 1/1
(100%)
1/1
(100%)
• HSCT
Artificial feeding 1 290 1/1
(100%)
1/1
(100%)
• All hematological malignancies
Opiate analgesia 1 290 1/1
(100%)
1/1
(100%)
• All hematological malignancies
Sepsis/infection 17 9170 9/16
(56%)
8/14
(57%)
• Acute leukemia
• All hematological malignancies
• AML
• HSCT
• Lymphoma
Hemodynamic instability 9 8095 6/8
(75%)
5/8
(62%)
• All hematological malignancies
• AML
• Cord HSCT
• HSCT
• Lymphoma
Multi organ failure 9 657 6/8
(75%)
5/6
(83%)
• All hematological malignancies
• HSCT
Respiratory distress/failure 13 8715 5/12
(42%)
5/10
(50%)
• Acute leukemia
• All hematological malignancies AML
• Cord HSCT
• HSCT
• Lymphoma
Cardiovascular function 5 711 3/5
(60%)
3/5
(60%)
• All hematological malignancies
• HSCT
• Acute leukemia
Decreased level of
consciousness
10 1169 3/9
(33%)
3/8
(37%)
• Acute leukemia
• All hematological malignancies
• HSCT
• Lymphoma
Renal dysfunction 8 8205 2/6
(33%)
2/3
(66%)
• Acute leukemia
• All hematological malignancies
• AML
• Cord HSCT
• HSCT
• Lymphoma
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Table 3 Attributes of commonly reported prognostic factors (Continued)
Fungal infection 4 382 2/4
(50%)
2/4
(50%)
• Acute leukemia
• All hematological malignancies
• HSCT
Liver dysfunction 7 478 3/7
(43%)
3/4
(75%)
• Acute leukemia
• AML
• Cord HSCT
• All hematological malignancies
• HSCT
Pneumonia 4 173 2/4
(50%)
0/1
(0%)
• All hematological malignancies
• Cord HSCT
• HSCT
CMV reactivation 1 86 1/1
100%
0/1
0%
• All hematological malignancies
Performance status 4 775 1/4
(25%)
1/4
(25%)
• Acute leukemia
• All hematological malignancies
Disease characteristics
Acute leukemia 11 9352 2/10
(20%)
4/10
(40%)
• All hematological malignancies
• Cord HSCT
• HSCT
Relapse or advanced
disease
10 862 4/10
(40%)
4/8
(50%)
• Acute leukemia
• All hematological malignancies
• AML
• Cord HSCT
• HSCT
HSCT 9 8617 1/8
(12%)
1/7
(14%)
• All hematological malignancies
• HSCT
Laboratory values
Liver enzymes 11 823 7/11
(64%)
5/6
(83%)
• Acute leukemia
• All hematological malignancies
• AML
• HSCT
Urea or creatinine 11 8294 5/10
(50%)
3/7
(43%)
• Acute leukemia
• All hematological malignancies
• AML
• Cord HSCT
• HSCT
Neutropenia or
leukopenia
15 9244 5/14
(36%)
5/12
(42%)
• All hematological malignancies
• AML
• HSCT
Thrombocytopenia 10 8614 5/9
(55%)
4/6
(67%)
• All hematological malignancies
• AML
• Cord HSCT
• HSCT
Coagulopathy 8 512 4/7
(57%)
3/4
(75%)
• Acute leukemia
• All hematological malignancies
• AML
• HSCT
• Lymphoma
Anemia 4 477 4/4
(100%)
4/4
(100%)
• All hematological malignancies
• HSCT
Blood pH 3 7960 2/3
(66%)
2/2
(100%)
• All hematological malignancies
Calcium 2 338 2/2
(100%)
2/2
(100%)
• All hematological malignancies
• HSCT
CRP 3 368 2/3
(66%)
2/2
(100%)
• All hematological malignancies
• AML
• HSCT
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survival. Symptoms related to bone marrow failure or
suppression, including anemia and coagulopathy, were
also predictive of mortality. Sepsis or the presence of
infection appeared to be predictive of mortality but the
magnitude of this association was moderate: 56% in
univariate testing and 57% in multivariable modelling. The
findings of this review suggest limited value in perform-
ance status as a prognostic factor, with only one of the
four studies which tested this variable finding it to be
statistically significant. No study included in this review
reported on clinician judgement, quality of life, comorbidi-
ties and symptom burden.
Disease characteristics
Disease stage (relapsed/advanced disease) did not appear
to be associated with survival and was significant in 40%
of studies that tested this factor (n = 4/10). A diagnosis
of leukemia was investigated as a prognostic factor in 11
studies (total sample n = 9352) and was significant in
univariate results in 20% of studies (n = 2/10) and in
multivariable results in 40% of studies (n = 4/10). A his-
tory of hematopoietic stem cell transplant also did not
appear to be associated with increased risk of mortality
and was significant in only 12% of univariate results
(n = 1/8) and 14% of multivariable results (n = 1/7) in a
total sample of 8617 people.
Laboratory blood values
Laboratory blood values related to bone marrow suppres-
sion or failure and active cancer such as neutropenia,
thrombocytopenia, anemia and coagulopathy were moder-
ately associated with increased risk of mortality. Abnormal
blood PH, elevated calcium, elevated liver enzymes and
elevated urea and creatinine were also predictive of
mortality. Hypoalbuminemia did not appear to be associ-
ated with increased risk of mortality in the 5 studies which
investigated this prognostic factor [30, 35, 44, 52, 57], and
was significant in 40–50% of results (n = 2/5 univariate
and n = 2/4multivariable) with a total sample of 570 par-
ticipants. A range of other factors was tested with varying
results (see Table 3 and Additional file 1 for further details
of prognostic factors).
Discussion
Prognostic factors
The aim of this review was to identify the current evidence
regarding prognosticating in the final 3 months of life for
people with a hematological malignancy, for the purpose of
informing provision of palliative care as patients transition
to the end of life. This review also aimed to identify gaps in
the literature and guide future research. Not surprisingly,
our findings substantiate previous research that demon-
strates critical illness and the need for aggressive life
supporting measures are associated with increased risk of
mortality for patients with a cancer diagnosis [64, 65].
Receiving mechanical ventilation and vasopressor support
were among the strongest prognostic factors for people
with a hematological malignancy in the ICU. As is found in
the solid tumor population, multi-organ failure, organ
failure (liver, renal or cardiac) and hemodynamic instability
were associated with worse survival for people with a
hematological malignancy.
The studies included in our review did not report on, or
confirm the significance of, many of the key prognostic
factors associated with increased risk of mortality at the
end of life in the solid tumour population. This includes
Table 3 Attributes of commonly reported prognostic factors (Continued)
Hematocrit 4 7859 1/3
(33%)
2/4
(50%)
• All hematological malignancies
Hypoalbuminemia 5 570 2/5
(40%)
2/4
(50%)
• All hematological malignancies
• AML
• HSCT
Lactate 2 133 2/2
(100%)
2/2
(100%)
• HSCT
LDH 2 7737 2/2
(100%)
2/2
(100%)
• All hematological malignancies
• HSCT
Sodium 2 338 ½
(50%)
2/2
(100%)
• All hematological malignancies
• HSCT
Bicarbonate 1 48 1/1
(100%)
1/1
(100%)
• HSCT
Pro-calcitonin 1 48 1/1
(100%)
1/1
(100%)
• HSCT
Uric acid 1 48 1/1
(100%)
1/1
(100%)
• HSCT
N.B. Only studies which reported on the prognostic indicator are included in the univariate and multivariable analysis reporting
N.B Prognostic factors that had a large overall sample were predominantly made up of the numbers from Hampshire et al. [48] (n = 7689)
HSCT Hematopoietic stem cell transplant/AML acute myeloid leukemia
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prognostic factors such as performance status, presence of
co-morbidities, symptom burden, quality of life, disease
stage or symptoms of anorexia-cachexia syndrome [11, 66].
This is likely to be partially due to the fact that these factors
were not adequately tested in the studies in this review,
which were largely focused on prognostic factors routinely
measured in the ICU setting in the context of acute deteri-
oration. This could also be partly due to the fact that the
patient cohort in many of the studies included in this
review were dying from acute critical illness in contrast to
slower, more predictable disease progression as commonly
seen in the solid tumour population [67]. Sudden deterior-
ation to a terminal event is reported to be a common
occurrence in the hematology setting leading to issues with
prognosticating and the provision of palliative care [6].
Prognostic factors that are only present in the context of
acute deterioration and critical illness (i.e. mechanical venti-
lation and vasopressor support) are not likely to be useful
in facilitating effective and timely integration of palliative
care, as they are present too late in the illness trajectory.
However, they are useful for identifying the appropriate
time to transition the care of a patient with a hematological
malignancy to align with a palliative approach as they enter
the terminal phase.
Several palliative prognostic tools exist, predicting time
frames of survival and risk of death for people with
chronic illness and solid tumors as they near the end of
life. However, it is unclear if these tools are applicable to
the specific illness trajectory experienced by people with a
hematological malignancy [68]. A number of studies exist
highlighting key prognostic factors in the final months of
life for people with a solid tumor diagnosis. It is also un-
clear if these factors can inform palliative care provision
and transitioning of patients to the end of life in the
hematology setting, due to the significant gap in the litera-
ture highlighted in this review [11]. Disease progression
for certain hematological malignancies may be more
closely aligned to trajectories of people with organ failure
and advanced non-oncological diseases such as respiratory
and heart failure or human immunodeficiency virus and
acquired immune deficiency syndrome [69]. For these
patients, the illness trajectory is gradual and marked with
episodes of acute deterioration which may lead to death,
or be followed by some recovery. In this trajectory, death
is sudden and seemingly unexpected [70]. In this clinical
scenario it is important to integrate palliative care and
plan for potential palliative needs early for at-risk patients,
prior to acute and rapid deterioration. It is acknowledged
the clinical course of people with hematological malignan-
cies varies significantly between disease types and within
an individual disease depending on a range of factors [4].
It is possible that some people with a hematological malig-
nancy, particularly those with less aggressive disease, will
share a similar trajectory to people with solid tumours,
while others will not. The differences in illness trajectories
should impact on the timing and manner in which pallia-
tive care is integrated and provided [70]. It is likely that all
people with a hematological malignancy have been treated
in the same manner and models of care and in which their
solid tumour counterparts are treated, negatively impact-
ing on palliative care integration and provision [71].
Further research is needed to address these unanswered
questions and inform clinical practice.
Quality of life and symptom burden was not assessed in
the included studies, despite these factors being associated
with increased risk of mortality at other times in the illness
trajectory for people with a hematological malignancy, and
in people with other types of malignancies [11, 66, 72, 73].
It is acknowledged that these factors are difficult to assess
retrospectively, as was the methodology of most studies.
The majority of the studies in this review did not assess the
effect of performance status and number of co-morbidities
despite these factors also being reported as predictive of
survival for people with a hematological malignancy at
other stages in the illness trajectory; for example prior to
stem cell transplantation [2, 74]. Surprisingly, none of the
studies investigated clinician judgement (the clinicians’ pre-
diction of survival) which, despite having limitations, is still
considered to be useful in clinical practice, especially when
used in combination with known prognostic factors and/or
tools [22, 75]. Furthermore, the widely used surprise
question “would you be surprised if this patient died in the
next 12 months” [16] has not been tested in the hematology
setting to the best of our knowledge. The body of literature
identified in this review, did not adequately test all
potentially relevant prognostic factors for people with a
hematological malignancy in the final 3 months of life, lead-
ing to significant gaps in knowledge.
Unique population of ‘terminal ill’ patients
While there are no standard criteria for defining the ‘end
of life’ or ‘terminal phase’, a median survival of 3 months
or less is often used to identify a terminal population [11].
Despite being close to death, most of the study popula-
tions did not appear to meet many of the criteria often
used to described people in the terminal phase, such as:
being recognised as approaching death; having ‘exhausted’
all curative treatment options; evidence of progressive
malignant disease; or having goals redefined and focused
towards symptom management [11]. People with a
hematological malignancy often do not present as ‘termin-
ally ill’ patients in their final months of life; they appear to
have a shorter terminal phase compared to people with a
solid tumor diagnosis. Therefore, current definitions and
notions of the ‘terminal phase’ may not be suited to people
with a hematological malignancy in regards to the
provision of palliative care and end-of-life care.
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The body of literature found in this review supports the
notion that people with a hematological malignancy are
reported to have a fluctuating illness trajectory, deteriorate
rapidly to a terminal event and receive intense medical in-
terventions often close to death [5, 76, 77]. It is difficult to
establish the futility of aggressive interventions for people
with a hematological malignancy as the absolute absence of
benefit is often hard to identify and may be dependent on
the particular person and their family [58]. However, the
utility verse harm associated with such interventions should
be determined. A person’s quality of life between episodes
of acute illness must also be taken into consideration when
considering palliative care integration and provision. The
literature reflects that people with a hematological malig-
nancy experience significant symptom burden near the end
of life [78]. Due to this cohort’s fluctuating and unpredict-
able illness trajectory, identification of risk of deteriorating
and dying may be more useful than predicting time frames
for survival. The best way to provide people with a
hematological malignancy with effective palliative and end-
of-life care may be to: a) identify those who are at risk of
deteriorating and dying [16]; and b) integrate palliative care
alongside curative or life prolonging care, which is recom-
mended in the hematology setting [10, 16].
Identifying people with progressive chronic illness who
are at risk of dying, as a means of highlighting potential
palliative needs, is a concept that is gaining momentum,
and has become key a strategic policy in many health
care services [79, 80]. This concept is largely unexplored
in the hematology setting. Research is needed to explore
this concept and the clinical indicators that are associ-
ated with risk of deteriorating and dying for people with
a hematological malignancy, prior to acute deterioration.
It is argued that too much emphasis is placed on pre-
dicting mortality and time frames of survival and too lit-
tle is placed on planning for potential palliative care
needs [81]. Future research needs to study patients with
a hematological malignancy in all health care settings
(in-patient and out-patient, acute and non-acute) prior
to acute physiological deterioration. Additionally, studies
are needed to investigate the impact of identifying at-
risk patients and the notion of integrating and providing
palliation along-side curative or life-prolonging care [5].
The literature reports there are challenges associated
with integrating, and the provision of, palliative care in
the hematology setting [5]. This includes, but is not lim-
ited to, the fluctuating and unpredictable illness trajec-
tory experienced by many people, unclear goals of care
in the context of new therapies and clinical trials, and a
lack of knowledge of palliative care amongst, patients,
families and health care professionals [5]. Additionally,
the explosion of new therapies (immunologic and tar-
geted agents) in the hematology setting is altering the
disease course of many malignancies leading to further
difficulties in prognosticating [15]. Previous research has
demonstrated benefits associated with early integration
of palliative care services for people with life-threatening
illness (i.e. referral to specialist palliative care service on
diagnosis of malignancy) [82, 83]. To the best of our
knowledge, the effects of early palliative care integration
have not yet been studied rigorously in the hematology
setting in interventional studies. Studies exploring
Advance Care Planning prior to stem cell transplantation
reported it was associated with benefits for the patient
and their carer, and was not associated with reduced sur-
vival [84–86]. These studies were observational in nature
therefore results must be viewed with caution. However,
the findings demonstrate that discussions and planning
for the end of life can be successfully provided alongside
aggressive treatment of life-prolonging or curative intent
in the hematology setting.
Lack of focus on palliative care
Studies with a palliative care focus, to inform this re-
view, were scant within the literature. None of the in-
cluded studies set in the ICU or acute care setting
discussed identifying palliative care needs or palliative
care integration or provision, despite their sample having
a high mortality rate. It is acknowledged that this was
not the aim of the included studies.
Of interest, during preliminary searching a large body
of literature was found regarding prognosticating in the
hematology setting that is focused on the earlier stages
in the disease trajectory, such as upon diagnosis or pre-
stem cell transplantation. Pre-stem cell transplantation,
the presence and number of co-morbidities appears to
be predictive of mortality and the Hematopoietic Stem
Cell Specific Comorbidity Index has been developed for
use [74]. Prognosticating for patients with a newly diag-
nosed hematological malignancy focuses on prognostic
factors such as age, stage of disease, histology, and re-
ceptor status [2]. A number of prognostic tools exist for
certain hematological malignancies upon diagnosis, in-
cluding but not limited to, the International Prognostic
Scoring System and the International Prognostic Indica-
tor and related versions [2]. However, as the disease ad-
vances and the person’s physical condition deteriorates,
issues such as malnutrition, poor performance, bleeding
and infection are reported to be associated with the end
of life for people with a hematological malignancy [57].
These factors have not been adequately explored in the
literature. The study by Kripp and colleagues’ investigat-
ing prognostic factors of people admitted to a palliative
care unit was the only study to test a range of prognostic
factors traditionally associated with advanced illness,
such as opiate use, requiring artificial feeding, poor
performance and hypoalbuminemia [57]. Additionally,
this study investigated prognostic factors associated with
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signs of end-stage hematological malignancies including
anemia, thrombocytopenia and requiring transfusion
support [76, 87, 88]. It is difficult to establish the signifi-
cance of prognostic factors that were tested in few stud-
ies. A significant gap in the literature exists regarding
prognostic factors that are relevant outside the ICU,
prior to acute physiological deterioration.
Limitations
A major limitation of this review was a lack of variation in
study settings and designs. The studies identified in this
review were predominantly focused on people being
treated aggressively in the in-patient setting, particularly
in the ICU. It is not clear if any of the prognostic factors
identified in these studies are transferable to the broader
hematology population. Most studies (n = 25) employed a
retrospective design and were therefore only able to assess
prognostic factors that were routinely collected in clinical
practice for association with increased risk of mortality.
The lack of variation in study settings and samples in this
body of literature significantly limits the generalisability of
findings. However, the aim of the review was to identify
the current knowledge base regarding prognosticating in
the final 3 months of life, identify gaps in knowledge and
guide future research. As the majority of studies were set
in the ICU (n = 24) only prognostic factors that are rou-
tinely measured on admission to, or in this setting, could
be assessed. This led to significant bias of the potential
prognostic factors studied. Clinical practice and the type
of data collected in the ICU are often very different to that
of a ward, out-patient department, palliative care unit, or
in the community. Only two studies investigated prognos-
ticating for people treated with palliative intent [56, 57].
Another limitation of the review was the heterogeneity of
the prognostic factors tested and the measurements uti-
lised in studies which made the collation and comparisons
across study findings difficult. In addition, differences in
statistical analyses and varying end-points for survival
have complicated the clinical applicability of findings [11].
Our review had some methodological limitations. It is ac-
knowledged that the inclusion criterion for survival times
excluded more recent studies set in the ICU, in which sur-
vival rates for people with a hematological malignancy have
improved in recent years. However, the focus of this review
was to identify prognostic factors for people who were
nearing the end of their life therefore this inclusion criter-
ion was considered practical and appropriate. Similar cri-
teria has been previously used in similar reviews exploring
survival prediction at the end of life [11, 22]. Additionally,
non-English language studies were excluded. It is possible
that some potentially relevant studies were missed however
it is unlikely that papers presenting the best available evi-
dence were overlooked as the prominent international
hematology journals are published in English. Also, a small
selection of key databases was searched for this review. It is
unlikely that any noteworthy studies were missed in
database searching, as this was supplemented by Google
Scholar searching and hand searching via screening refer-
ence lists of relevant papers.
Overall, the quality of the articles was of a moderate to
high standard, with only one study graded as low evidence
as per the QUIPS tool. The clinical significance of many
of the prognostic factors identified may be hindered by
methodological flaws in the studies including: a) small
sample size; b) single centre; c) measurement of prognos-
tic factors varied between studies; d) lack of adjustment
for important prognostic factors such as performances
status; e) different reporting of survival end-points; and f)
the retrospective nature of most studies [11]. Certain
prognostic factors identified as significant in univariate
analysis, were not identified as independently associated
with increased risk of mortality in multivariable regression
modelling, thus limiting the results of such findings. Re-
sults must also be viewed with caution as many studies
tested more potential prognostic factors than warranted
by their small sample size. Additionally, none of the stud-
ies described the admission policy to the ICU or palliative
care unit the study was set in, or referral policy to the
specialist palliative care unit. Therefore it was difficult to
establish if study samples were representative of a larger
population and if results are generalizable.
Unanswered questions
Our objective was to identify the key prognostic factors
associated with increased risk of mortality in the final
3 months of life for people with a hematological malignancy
to inform palliative care provision as patients transition to
the end of life. Gaps in the body of knowledge have also
been identified to guide future research. Due to significant
limitations in the findings, the results are not likely to be
useful in clinical decision-making; rather, the findings high-
light many unanswered questions and serve to inform future
research. The lack of focus on prognosticating near the end
of life, identifying risk of deteriorating and dying, provision
of palliative care, and transitioning to the end of life for
people with a hematological malignancy, supports the need
for more research in this area [22]. The best way forward
may be to investigate clinical indicators which identify risk
of deteriorating and dying, rather than prognostic factors
that predict time frames of survival due to the unpredictable
nature of hematological malignancies. Study samples must
include people prior to acute deterioration and in a range of
settings. Studies are needed that are prospective, multi-
centred, have large sample sizes and are methodologically
rigorous in multivariable testing. Further research is needed
investigating the importance of clinical indicators such as
performance status, symptoms, clinician prediction (specific-
ally the surprise question) and potentially quality of life.
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Conclusion
The body of literature reporting prognostic factors at the end
of life for people with a hematological malignancy, is pre-
dominantly focused on people who have already deteriorating
and are receiving aggressive treatment. Due to the unpredict-
able and fluctuating illness trajectory experience in this popu-
lation, research is needed to identify risk of dying, prior to
acute physiological deterioration, to improve palliative and
end-of-life care delivery. Exact survival times cannot be
predicted with certainty, particularly in this population.
However, identifying people who have limited time remaining
or are at risk of dying can enable clinicians to provide quality
care, and allow patients and families the opportunity to plan
for the future and have their wishes known.
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